Astellas Bid For OSI Of U.S. Hampered By Growing Stock Value
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma may have to extend its bid to buy U.S.-based OSI Pharmaceuticals at least once more because of the target's continuing higher stock price